BRCA mutations and prostate cancer: should urologist improve daily clinical practice?
NGS analysis for BRCA genetic testing using FFPE tissue in the clinical setting of patients with high-grade and/or metastatic PCa appears to be a valuable tool, not only for therapeutic purposes, but also to identify families with genetic predisposition who may be underdiagnosed according to canonical criteria.
Authors
- Pietro Pepe (ORCID: https://orcid.org/0000-0002-8375-4419)
- Ludovica Pepe
- Simona Vatrano (ORCID: https://orcid.org/0000-0003-4022-4343)
- Norbert Vella
- Cristina Mauceri
- Renato Scillieri
- Filippo Fraggetta (ORCID: https://orcid.org/0000-0002-0040-9987)
- C. Taranto
- Cristina Alario
- Alessia Chiarandà
Institutions
- Newborn Screening Ontario (CA)
- Instituto de Filosofía (ES)
- Ospedale Cannizzaro (IT)
- Azienda Ospedaliero Universitaria Policlinico "G.Rodolico - San Marco" (IT)
- European Gravitational Observatory (IT)
Publication Details
- Journal
- Archivio Italiano di Urologia e Andrologia
- Published
- 2025-04-17
- DOI
- https://doi.org/10.4081/aiua.2025.13635
- Citations
- 5
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 7.59